First name
Susan
Middle name
C
Last name
Lipsett

Title

Respiratory virus testing and clinical outcomes among children hospitalized with pneumonia.

Year of Publication

2022

Number of Pages

693-701

Date Published

06/2022

ISSN Number

1553-5606

Abstract

BACKGROUND: Despite the increased availability of diagnostic tests for respiratory viruses, their clinical utility for children with community-acquired pneumonia (CAP) remains uncertain.

OBJECTIVE: To identify patterns of respiratory virus testing across children's hospitals prior to the COVID-19 pandemic and to determine whether hospital-level rates of viral testing were associated with clinical outcomes.

DESIGN, SETTING, AND PARTICIPANTS: Multicenter retrospective cohort study of children hospitalized for CAP at 19 children's hospitals in the United States from 2010-2019.

MAIN OUTCOMES AND MEASURES: Using a novel method to identify the performance of viral testing, we assessed time trends in the use of viral tests, both overall and stratified by testing method. Adjusted proportions of encounters with viral testing were compared across hospitals and were correlated with length of stay, antibiotic and oseltamivir use, and performance of ancillary laboratory testing.

RESULTS: There were 46,038 hospitalizations for non-severe CAP among children without complex chronic conditions. The proportion with viral testing increased from 38.8% to 44.2% during the study period (p < .001). Molecular testing increased (27.2% to 40.0%, p < .001) and antigen testing decreased (33.2% to 7.8%, p < .001). Hospital-specific adjusted proportions of testing ranged from 10.0% to 83.5% and were not associated with length of stay, antibiotic use, or antiviral use. Hospitals that performed more viral testing did not have lower rates of ancillary laboratory testing.

CONCLUSIONS: Viral testing practices varied widely across children's hospitals and were not associated with clinically important process or outcome measures. Viral testing may not influence clinical management for many children hospitalized with CAP.

DOI

10.1002/jhm.12902

Alternate Title

J Hosp Med

PMID

35747928
Inner Banner
Publication Image
Inner Banner
Publication Image

Title

Antibiotics and outcomes of CF pulmonary exacerbations in children infected with MRSA and Pseudomonas aeruginosa.

Year of Publication

2022

Number of Pages

Date Published

08/2022

ISSN Number

1873-5010

Abstract

BACKGROUND: Limited data exist to inform antibiotic selection among people with cystic fibrosis (CF) with airway infection by multiple CF-related microorganisms. This study aimed to determine among children with CF co-infected with methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa (Pa) if the addition of anti-MRSA antibiotics to antipseudomonal antibiotic treatment for pulmonary exacerbations (PEx) would be associated with improved clinical outcomes compared with antipseudomonal antibiotics alone.

METHODS: Retrospective cohort study using data from the CF Foundation Patient Registry-Pediatric Health Information System linked dataset. The odds of returning to baseline lung function and having a subsequent PEx requiring intravenous antibiotics were compared between PEx treated with anti-MRSA and antipseudomonal antibiotics and those treated with antipseudomonal antibiotics alone, adjusting for confounding by indication using inverse probability of treatment weighting.

RESULTS: 943 children with CF co-infected with MRSA and Pa contributed 2,989 PEx for analysis. Of these, 2,331 (78%) PEx were treated with both anti-MRSA and antipseudomonal antibiotics and 658 (22%) PEx were treated with antipseudomonal antibiotics alone. Compared with PEx treated with antipseudomonal antibiotics alone, the addition of anti-MRSA antibiotics to antipseudomonal antibiotic therapy was not associated with a higher odds of returning to ≥90% or ≥100% of baseline lung function or a lower odds of future PEx requiring intravenous antibiotics.

CONCLUSIONS: Children with CF co-infected with MRSA and Pa may not benefit from the addition of anti-MRSA antibiotics for PEx treatment. Prospective studies evaluating optimal antibiotic selection strategies for PEx treatment are needed to optimize clinical outcomes following PEx treatment.

DOI

10.1016/j.jcf.2022.08.001

Alternate Title

J Cyst Fibros

PMID

35945130
Inner Banner
Publication Image
Inner Banner
Publication Image

Title

Mycoplasma Pneumoniae Testing and Treatment Among Children With Community-Acquired Pneumonia.

Year of Publication

2021

Number of Pages

760-763

Date Published

2021 Jul

ISSN Number

2154-1671

Abstract

<p><strong>OBJECTIVES: </strong>To describe testing and treatment practices for () among children hospitalized with community-acquired pneumonia (CAP).</p>

<p><strong>METHODS: </strong>We conducted a retrospective cohort study using the Pediatric Health Information Systems database. We included children 3 months to 18 years old hospitalized with CAP between 2012 and 2018 and excluded children who were transferred from another hospital and those with complex chronic conditions. We examined the proportion of patients receiving testing and macrolide therapy at the hospital level and trends in testing and macrolide prescription over time. At the patient level, we examined differences in demographics, illness severity (eg, blood gas, chest tube placement), and outcomes (eg, ICU admission, length of stay, readmission) among patients with and without testing.</p>

<p><strong>RESULTS: </strong>Among 103 977 children hospitalized with CAP, 17.3% underwent testing and 31.1% received macrolides. We found no correlation between testing and macrolide treatment at the hospital level ( = 0.05; = .11). Patients tested for were more likely to have blood gas analysis (15.8% vs 12.8%; &lt; .1), chest tube placement (1.4% vs 0.8%; &lt; .1), and ICU admission (3.1% vs 1.4%; &lt; .1). testing increased (from 15.8% to 18.6%; &lt; .001), and macrolide prescription decreased (from 40.9% to 20.6%; &lt; .001) between 2012 and 2018.</p>

<p><strong>CONCLUSIONS: </strong>Nearly one-third of hospitalized children with CAP received macrolide antibiotics, although macrolide prescription decreased over time. Clinicians were more likely to perform testing in children with severe illness, and testing and macrolide treatment were not correlated at the hospital level.</p>

DOI

10.1542/hpeds.2020-005215

Alternate Title

Hosp Pediatr

PMID

34583319
Inner Banner
Publication Image
Inner Banner
Publication Image

Title

Short- Versus Prolonged-Duration Antibiotics for Outpatient Pneumonia in Children.

Year of Publication

2021

Number of Pages

Date Published

2021 Mar 18

ISSN Number

1097-6833

Abstract

<p><strong>OBJECTIVE: </strong>To identify practice patterns in the duration of prescribed antibiotics for the treatment of ambulatory children with community-acquired pneumonia (CAP) and to compare the frequency of adverse clinical outcomes between children prescribed short- versus prolonged-duration antibiotics.</p>

<p><strong>STUDY DESIGN: </strong>We performed a retrospective cohort study from 2010-2016 using the IBM Watson MarketScan Medicaid Database, a claims database of publicly-insured patients from 11 states. We included children 1-18 years old with outpatient CAP who filled a prescription for oral antibiotics (N = 121,846 encounters). We used multivariable logistic regression to determine associations beween the duration of prescribed antibiotics (5-9 days vs 10-14 days) and subsequent hospitalizations, new antibiotic prescriptions, and acute care visits. Outcomes were measured during the 14 days following the end of the dispensed antibiotic course.</p>

<p><strong>RESULTS: </strong>The most commonly prescribed duration of antibiotics was 10 days (82.8% of prescriptions), and 10.5% of patients received short-duration therapy. During the follow-up period, 0.2% of patients were hospitalized, 6.2% filled a new antibiotic prescription, and 5.1% had an acute care visit. Compared with the prolonged-duration group, the adjusted odds ratios for hospitalization, new antibiotic prescriptions, and acute care visits in the short-duration group were 1.16 (95% CI: 0.80-1.66), 0.93 (95% CI: 0.85-1.01), and 1.06 (95% CI: 0.98-1.15), respectively.</p>

<p><strong>CONCLUSIONS: </strong>Most children treated for CAP as outpatients are prescribed at least 10 days of antibiotic therapy. Among pediatric outpatients with CAP, no significant differences were found in rates of adverse clinical outcomes between patients prescribed short- versus prolonged-duration antibiotics.</p>

DOI

10.1016/j.jpeds.2021.03.017

Alternate Title

J Pediatr

PMID

33745996
Inner Banner
Publication Image
Inner Banner
Publication Image

Title

Antibiotic Choice and Clinical Outcomes in Ambulatory Children with Community-Acquired Pneumonia.

Year of Publication

2020

Number of Pages

Date Published

2020 Oct 09

ISSN Number

1097-6833

Abstract

<p><strong>OBJECTIVES: </strong>To describe antibiotic prescribing patterns in ambulatory children with community acquired pneumonia, and to assess the relationship between antibiotic selection and clinical outcomes.</p>

<p><strong>STUDY DESIGN: </strong>This was a retrospective cohort study of ambulatory Medicaid-enrolled children 0-18 years of age diagnosed with CAP from 2010-2016. The exposure was antibiotic class: narrow-spectrum (aminopenicillins), broad-spectrum (amoxicillin/clavulanate and cephalosporins), macrolide monotherapy, macrolides with narrow-spectrum antibiotics, or macrolides with broad-spectrum antibiotics. The associations between antibiotic selection and the outcomes of subsequent hospitalization and development of severe pneumonia (chest drainage procedure, intensive care admission, mechanical ventilation) were assessed, controlling for measures of illness severity.</p>

<p><strong>RESULTS: </strong>Among 252,177 outpatient pneumonia visits, macrolide monotherapy was used in 43.2%, narrow-spectrum antibiotics in 26.1%, and broad-spectrum antibiotics in 24.7%. A total of 1488 children (0.59%) were subsequently hospitalized and 117 (0.05%) developed severe pneumonia. Compared with children receiving narrow-spectrum antibiotics, the odds of subsequent hospitalization were higher in children receiving broad-spectrum antibiotics (aOR=1.34 [95%CI 1.17-1.52]) and lower in children receiving macrolide monotherapy (aOR=0.64 [95%CI 0.55-0.73]) and macrolides with narrow-spectrum antibiotics (aOR=0.62 [95%CI 0.39-0.97]). Children receiving macrolide monotherapy had lower odds of developing severe pneumonia than children receiving narrow-spectrum antibiotics (aOR=0.56, 95%CI 0.33-0.93). However, the absolute risk difference was &lt;0.5% for all analyses.</p>

<p><strong>CONCLUSIONS: </strong>Macrolides are the most commonly prescribed antibiotic for ambulatory children with CAP. Subsequent hospitalization and severe pneumonia are rare. Future efforts should focus on reducing broad-spectrum and macrolide antibiotic prescribing.</p>

DOI

10.1016/j.jpeds.2020.10.005

Alternate Title

J Pediatr

PMID

33045236
Inner Banner
Publication Image
Inner Banner
Publication Image

Title

Predictors of Bacteremia in Children Hospitalized With Community-Acquired Pneumonia.

Year of Publication

2019

Number of Pages

Date Published

2019 Sep 13

ISSN Number

2154-1671

Abstract

<p><strong>BACKGROUND AND OBJECTIVES: </strong>The yield of blood cultures in children hospitalized with community-acquired pneumonia (CAP) is low. Characteristics of children at increased risk of bacteremia remain largely unknown.</p>

<p><strong>METHODS: </strong>We conducted a secondary analysis of a retrospective cohort study of children aged 3 months to 18 years hospitalized with CAP in 6 children's hospitals from 2007 to 2011. We excluded children with complex chronic conditions and children without blood cultures performed at admission. Clinical, laboratory, microbiologic, and radiologic data were assessed to identify predictors of bacteremia.</p>

<p><strong>RESULTS: </strong>Among 7509 children hospitalized with CAP, 2568 (34.2%) had blood cultures performed on the first day of hospitalization. The median age was 3 years. Sixty-five children with blood cultures performed had bacteremia (2.5%), and 11 children (0.4%) had bacteremia with a penicillin-nonsusceptible pathogen. The prevalence of bacteremia was increased in children with a white blood cell count &gt;20 × 10 cells per µL (5.4%; 95% confidence interval 3.5%-8.1%) and in children with definite radiographic pneumonia (3.3%; 95% confidence interval 2.4%-4.4%); however, the prevalence of penicillin-nonsusceptible bacteremia was below 1% even in the presence of individual predictors. Among children hospitalized outside of the ICU, the prevalence of contaminated blood cultures exceeded the prevalence of penicillin-nonsusceptible bacteremia.</p>

<p><strong>CONCLUSIONS: </strong>Although the prevalence of bacteremia is marginally higher among children with leukocytosis or radiographic pneumonia, the rates remain low, and penicillin-nonsusceptible bacteremia is rare even in the presence of these predictors. Blood cultures should not be obtained in children hospitalized with CAP in a non-ICU setting.</p>

DOI

10.1542/hpeds.2019-0149

Alternate Title

Hosp Pediatr

PMID

31519736
Inner Banner
Publication Image
Inner Banner
Publication Image

Title

Higher C6 enzyme immunoassay index values correlate with a diagnosis of noncutaneous Lyme disease.

Year of Publication

2019

Number of Pages

160-164

Date Published

2019 Jun

ISSN Number

1879-0070

Abstract

<p>The correlation between the Food and Drug Administration-cleared C6 enzyme immunoassay (EIA) C6 index values and a diagnosis of Lyme disease has not been examined. We used pooled patient-level data from 5 studies of adults and children with Lyme disease and control subjects who were tested with the C6 EIA. We constructed a receiver operating characteristic curve using regression clustered by study and measured the area under the curve (AUC) to examine the accuracy of the C6 index values in differentiating between patients with noncutaneous Lyme disease and control subjects. In the 4821 included patients, the C6 index value had excellent ability to distinguish between patients with noncutaneous Lyme disease and control subjects [AUC 0.99; 95% confidence interval (CI) 0.99-1.00]. An index value cut point of ≥3.0 had a sensitivity of 90.9% (95% CI, 87.8-93.3) and specificity of 99.0% (95% CI, 98.6-99.2%) for Lyme disease.</p>

DOI

10.1016/j.diagmicrobio.2018.12.001

Alternate Title

Diagn. Microbiol. Infect. Dis.

PMID

30642722
Inner Banner
Publication Image
Inner Banner
Publication Image

Title

Utility of Blood Culture Among Children Hospitalized With Community-Acquired Pneumonia.

Year of Publication

2017

Number of Pages

Date Published

2017 Aug 23

ISSN Number

1098-4275

Abstract

<p><strong>BACKGROUND AND OBJECTIVES: </strong>National guidelines recommend blood cultures for children hospitalized with presumed bacterial community-acquired pneumonia (CAP) that is moderate or severe. We sought to determine the prevalence of bacteremia and characterize the microbiology and penicillin-susceptibility patterns of positive blood culture results among children hospitalized with CAP.</p>

<p><strong>METHODS: </strong>We conducted a cross-sectional study of children hospitalized with CAP in 6 children's hospitals from 2007 to 2011. We included children 3 months to 18 years of age with discharge diagnosis codes for CAP using a previously validated algorithm. We excluded children with complex chronic conditions. We reviewed microbiologic data and classified positive blood culture detections as pathogens or contaminants. Antibiotic-susceptibility patterns were assessed for all pathogens.</p>

<p><strong>RESULTS: </strong>A total of 7509 children hospitalized with CAP were included over the 5-year study period. Overall, 34% of the children hospitalized with CAP had a blood culture performed; 65 (2.5% of patients with blood cultures; 95% confidence interval [CI]: 2.0%-3.2%) grew a pathogen. Streptococcus pneumoniae accounted for 78% of all detected pathogens. Among detected pathogens, 50 (82%) were susceptible to penicillin. Eleven children demonstrated growth of an organism nonsusceptible to penicillin, representing 0.43% (95% CI: 0.23%-0.77%) of children with blood cultures obtained and 0.15% (95% CI: 0.08%-0.26%) of all children hospitalized with CAP.</p>

<p><strong>CONCLUSIONS: </strong>Among children without comorbidities hospitalized with CAP in a non-ICU setting, the rate of bacteremia was low, and isolated pathogens were usually susceptible to penicillin. Blood cultures may not be needed for most children hospitalized with CAP.</p>

DOI

10.1542/peds.2017-1013

Alternate Title

Pediatrics

PMID

28835382
Inner Banner
Publication Image
Inner Banner
Publication Image